



On World Psoriasis Day UCB lends its support to raising awareness of a disease that affects 125 million people worldwide¹

Slough, UK – 28 October 2016: World Psoriasis Day (WPD), marked tomorrow, is especially dedicated to people with psoriasis/psoriatic arthritis.¹ The aim of WPD is to raise awareness and understanding, as well as improve access to treatments for people suffering from psoriasis/psoriatic arthritis. Psoriasis, is a common skin condition affecting up to 3% of the population of the United Kingdom and Ireland, but for patients it can be much more than just a skin condition, as it can affect people physically and psychologically.² There are various different types of psoriasis, and psoriasis can occur on any part of the body. Psoriatic Arthritis, is a particularly complex disease - an inflammatory arthritis associated with psoriasis.²

An overview of Psoriatic Arthritis (PsA):

- PsA develops in up to 30% of patients with symptoms of psoriasis
- Nearly 1 of 4 patients with psoriasis may have undiagnosed PsA
- Skin symptoms of PsA have a high impact on patients' psychological wellbeing and health-related quality of life
- The patient experience reflects this challenge, showing a critical gap in satisfaction with current therapies
- Achieving minimal disease activity (MDA, which includes articular and extra-articular control) is associated with better radiographic outcomes
- Lost productivity and disability caused by limitations in functioning and activities of daily living contribute to the total burden of PsA

In addition to WPD, the national UK patient charity, the Psoriasis Association, is running its own awareness campaign – during Psoriasis Awareness Week (29 October to 5 November) - to encourage patients and the public to tell their 'psoriasis stories' on social media and on their website (www.psoriasis-association.org.uk/awareness/paw-2016). The charity's **PsoriasisIS** campaign is aimed at getting as many people with experience of the disease to speak up and share what the condition means to them.³

At UCB we are passionate about enabling people with severe diseases to live the life they choose. We have a shared ambition to transform the lives of people living with severe diseases. We focus on neurology, including epilepsy and Parkinson's, and immunology disorders, which includes rheumatoid arthritis, ankylosing spondylitis, reactive arthritis, psoriatic arthritis - putting patients at the centre of our world.

For further information

Scott Fleming, Communications Director
UCB, British & Irish Isles
T: +44 770.277.7378
E: scott.fleming@ucb.com

Avril O'Connor, Brand Communications Manager
UCB, British & Irish Isles
T: 07736 120044
E: avril.oconnor@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7,700 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statements - UCB

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

References:

1. World Psoriasis Day: <http://www.worldpsoriasisday.com/> Accessed October 2016
2. Psoriasis Association Accessed October 2016
3. Psoriasis Association <https://www.psoriasis-association.org.uk/awareness/paw-2016> Accessed October 2016